Title Page 1 2 3 Interpretation of non-responders to SARS-CoV-2 vaccines using WHO International Standard 4 5 Qiang Zeng, MD^{1*}, Xue Yang, MD^{2*}, Qi Gao, PhD³, Biao-yang Lin, PhD⁴, Yong-zhe Li, MD⁵, 6 Gang Huang, MD^{6†} and Yang Xu, MD, PhD^{4,6†} 7 ¹Health Management Institute, the Second Medical Center & National Clinical Research Center 8 for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China 9 10 ²Outpatient Department, the Second Medical Center & National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China 11 ³Beijing Hotgen Biotechnology Inc., Beijing, China 12 ⁴Zhejiang University, Hangzhou, China 13 ⁵Department of Laboratory Medicine, Peking Union Medical College Hospital, Beijing, China 14 ⁶Laboratory of Special Diagnosis & Shanghai Key Laboratory of Molecular Imaging, Shanghai 15 16 University of Medicine and Health Sciences, Shanghai, China 17 *These authors contributed equally to the study. [†]Correspondence: Gang Huang, MD; Yang Xu, MD, PhD, yxu1627@126.com 18 19 20 21 22 23 Keyword: COVID-19; vaccine; non-responders; WHO; international standard; CD4 cells; 24 CD8 cells; B cells; BAU/mL; IU/mL 25

ABSTRACT

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic with more than 485 millions infected. Questions about non-responders to SARS-CoV-2 vaccines remain unaddressed. Here, we report data from people after administering the complete dose of SARS-CoV-2 vaccines using the World Health Organization International Standard for anti-SARS-CoV-2 immunoglobulin. Our study showed that immune cells such as CD4 cells, CD8 cells, and B cells and anti-spike immunoglobulin G levels were significantly reduced in the elderly. There were 7.5% non-responders among the 18–59 yr group and 11.7% in the ≥60 yr group. A titer of anti-SARS-CoV-2 spike immunoglobulin G is blew 50 BAU/mL to be considered as non-responders at intervals of 30 to 90 days after the last vaccine dose. Booster vaccination may be recommended for non-responders to reduce the disease severity and mortality.

INTRODCTION

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic, infecting more than 485 million people and killing more than 6 million. Since December 2020 the World Health Organization (WHO) recommends vaccination against COVID-19, nine types of coronavirus disease 2019 (COVID-19) vaccines have been included in the emergency use list. Vaccination against COVID-19 is especially important in reducing severe illness and mortality. According to the data of the Centers for Disease Control and Prevention (CDC) in 2016-2017, the mortality rate caused by influenza virus was 0.13%.

In order to bring the COVID-19 pandemic under control as soon as possible and ensure that the mortality rate of COVID-19 is close to that caused by influenza virus, the prevention and treatment of children as well as elderly and immunocompromised people has emerged as a top priority at present. Sun et al. first reported that hospitalization and severe outcomes were similar in unvaccinated healthy individuals and immunocompromised patients who received full SARS-CoV-2 vaccination in the United States, suggesting that COVID-19 breakthrough infection after SARS-CoV-2 vaccination is associated with immune dysfunction. Hospitalization and severe outcomes were 21.1% and 1.9%, respectively, in unvaccinated healthy individuals, and 20.7% and 2.1%, respectively, in patients with immune dysfunction after 14 days following full vaccination, indicating that an immune barrier is not well established in immunocompromised patients after full vaccination and post-vaccination testing is necessary to identify immunocompromised individuals without specific immunity so they can be given additional prophylaxis after full vaccination. This study suggests that post-vaccination testing will help reduce mortality, showing the importance and urgency of post-vaccination assessments using an international standard.

To date, more than 5 billion people have been vaccinated against COVID-19. In clinical trials associated with COVID-19 vaccines, the effective COVID-19 vaccination reportedly elicits specific antibody responses. An effective humoral immune response is defined as $a \ge 4$ -fold

increase in antibody titers from baseline within 1–3 months of the vaccination procedure and is considered gold standard for assessing antibody protection in vaccinated recipients. ¹⁰⁻¹² In contrast, a non-responder is an individual who demonstrates no effective humoral immune response despite the completion of the suggested vaccination procedure. ¹³⁻¹⁴

During the promotion of vaccination, several factors affecting the response to the COVID-19 vaccines were taken into consideration, especially the reduced response to the COVID-19 vaccine in children, elderly people, and immunocompromised population. However, despite the completion of COVID-19 vaccination in the population as per the recommendations by WHO, the outcomes concerning the protective levels of antibody concentration and factors determining the identification of non-responders still remain inconclusive. ¹⁵⁻²⁵

To this end, in December 2020, WHO issued an international standard (IS) for the quantification of anti-SARS-CoV-2 immunoglobulin for post-vaccination testing. $^{26-27}$ This standard provides a unified benchmark for effective antibody protective concentrations after vaccination. In this clinical study, we analyzed 627 people that volunteered to participate in COVID-19 vaccination and subsequent assessment of antibody titers. After two doses of vaccination, the antibody titer was evidently increased by ≥ 4 times from baseline as the gold standard. Furthermore, the data using the WHO IS was comprehensively analyzed to provide insights for improving the efficacy of vaccines, help in reduction of breakthrough infections after vaccines, and ultimately to reduce the disease severity and mortality.

RESULTS

Immune characteristics of 627 cases prior to vaccination

There were 42.4% (266/627) individuals aged \geq 60 yr and 50.9% (319/627) male enrolled in the study (Table 1). In the 18–59 yr group, the medians [interquartile ranges (IQRs)] of ALC, CD4 cell count, CD8 cell count, B cell count, and NK cell count were 1,476 (1,168–1,875), 851 (677–1,151), 490 (357–632), 256 (179–367), and 193 (141–287)/mm³, respectively. On the contrary, in the \geq 60 yr group, the respective medians (IQRs) were 1,281 (1,023–1,520), 747 (562–955), 418 (288–544), 204 (138–303), and 234 (162–355)/mm³ (Table 1). In fact, the number of naïve lymphocytes, CD4 cells, CD8 cells, and B cells were significantly reduced in the elderly

- population than that in the 18–59 yr population (P < 0.001). Hence, these naïve immune cells
- wane significantly, while the NK cell counts increase significantly in the elderly people (Table 1,
- 121 Fig. 1A).

123

Anti-spike IgG levels in the 627 cases after complete vaccination

- We analyzed the anti-spike immunoglobulin (Ig)G levels after complete vaccination of the 627
- cases (Table 1). Post-vaccination testing was done at intervals of 14 to 90 days after the second
- vaccine dose. The anti-spike IgG seropositive rates were 99.7% in the 18–59 yr population and
- 98.9% in the \geq 60 yr population based on the cutoff (Table 1). However, the quantitative level of
- the anti-spike IgG was significantly lower in the ≥60 yr group (median 307.2, IQRs 118.2–417.3
- 129 BAU/mL) than that in the 18–59 yr group (median 416.8, IQRs 355.7–479.2 BAU/mL) (Table 1,
- Fig. 1B). The reference ranges (2.5–97.5 percentile) were 88.6–576.2 BAU/mL in the 18–59 yr
- group and 27.7–491.0 BAU/mL in the ≥60 yr group at 14–90 days after complete vaccination
- 132 (Table 2).

133

134

141

Characteristics of seroconversion after the complete dose

- Thereafter, we evaluated the vaccine-induced responses, based on the post-second-dose and pre-
- second-dose titers, using the 4-fold increase parameter (fold-index <4 or ≥4) (Table 2).
- 137 Remarkably, there were 7.5% non-responders (fold-index < 4) among the 18–59 yr group and
- 138 11.7% in the ≥60 yr group (Table 2, Fig. 1C), indicating that the positive rate of anti-spike IgG
- cannot represent the seroconversion rate. Therefore, the anti-spike IgG positivity or
- seroprevalence might not be a suitable predictor of seroconversion (fold–index ≥ 4).
- In the 18–59 yr group, the median (IQRs) levels of anti-spike IgG and the reference ranges were
- 143 115.8 (88.6–167.8) and 18.3–266.3 BAU/mL with fold-index < 4, respectively and 420.8 (369.9–
- 480.6) and 200.7–576.5 BAU/mL with fold-index ≥ 4 , respectively (P < 0.0001). In contrast, in
- the >60 yr group, the median (IORs) levels of anti-spike IgG and the reference ranges were 63.9
- 146 (35.1–106.9) and 5.4–317.8 BAU/mL with fold-index < 4, respectively and 346.0 (160.4–424.7)
- and 46.6–491.1 BAU/mL with fold-index \geq 4, respectively (P < 0.0001). The reference ranges
- 148 (1–99 percentile) for responders (fold–index \geq 4) were 43.9–592.0 BAU/mL in combination of
- the 18-59 yr group and the ≥ 60 yr group at 14-90 days after complete vaccination (Figure 1C).

We further observed that the seroconversion rate was significantly related to the proportion of certain naïve immune cells (Table 2). Particularly, the lymphocyte count was significantly different (P < 0.0001) between the fold-index <4 or \geq 4 groups. For instance, in the 18–59 vr group, the lymphocyte count was 1,130/mm³ [95% CI (1,007–1,252)/mm³] in the <4 group and 1,578/mm³ [95% CI (1,524–1,633)/mm³] in the >4 group. On the contrary, in the >60 yr group, the lymphocyte count was 1,015/mm³ [95% CI (888–1,143)/mm³] in the <4 group and $1,344/\text{mm}^3$ [95% CI 1,291–1,397)/mm³] in the ≥ 4 group. Similarly, the CD4 cell counts were significantly different (P < 0.0001) between the individuals with fold–index <4 and >4. For instance, in the 18–59 vr population, the CD4 cell count was 631/mm³ [95% CI (555–708)/mm³] versus 942/mm³ [95% CI (905–979)/mm³] in the <4 and ≥4 groups, respectively, while in the >60 vr age group, it was 563/mm³ [95% CI (494–631)/mm³] versus 818/mm³ [95% CI (777– 858)/mm 3] in the <4 and \geq 4 groups, respectively. With respect to the B cell count, there was a significant difference (P < 0.0001) between the individuals with fold–index < 4 and > 4. For example, in the 18–59 age group, the B cell count was 119/mm³ [95% CI (72–166)/mm³ versus 306/mm³ [95% CI (289–323)/mm³] in the <4 and ≥4 groups, respectively, whereas in the ≥60 yr age group, it was 74/mm³ [95% CI (60–88) /mm³] versus 248/mm³ [95% CI (231–266)/mm³] in the <4 and ≥4 groups, respectively. Regarding the CD8 cell count, a significant difference was noted only between the individuals with <4 and >4 fold-indices in the 18-59 yr age group $[414/\text{mm}^3 (95\% \text{ CI } 349-479/\text{mm}^3) \text{ versus } 532/\text{mm}^3 (95\% \text{ CI } 508-557/\text{mm}^3), P = 0.0081].$ However, the CD8 cell count in the ≥60 yr group and NK cell count in both the age groups did not portray any significant differences.

DISCUSSION

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

To the best of our knowledge, this is the first clinical study to report non-responders after administering the complete dose of inactivated SARS-CoV-2 vaccines using WHO International Standard (IS) for anti-SARS-CoV-2 immunoglobulin (Ig). Whether there is a humoral immune response following COVID-19 vaccination is a marker of population immunity. Typically, effective humoral immune response is defined as $a \ge 4$ -fold rise in antibody titers from baseline within 1-3 months of the vaccination schedule. The use of anti-SARS-CoV-2 assays with the

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

WHO IS can facilitate the comparison of the strength of the humoral immune response between individuals, making the data more accurate and providing reliable data for the COVID-19 vaccine booster. Therefore, adequate clinical trials are necessary regarding the assessment of immune characteristics of individuals prior to vaccine booster shot, such that the mortality in the pandemic may be quickly reduced. We used an anti-SARS-CoV-2 spike quantitative IgG kit (COVID-SeroKlir Kantaro SARS-CoV-2 IgG Ab Kit) approved by the Food and Drug Administration (FDA) under Emergency Use Authorization (EUA) with the WHO IS. This kit has been extensively evaluated in many clinical studies, including neutralizing antibodies after SARS-CoV-2 infection, immunological memory to SARS-CoV-2, convalescent plasma treatment of severe COVID-19, and antibody responses to mRNA vaccines in healthy people and patients. 30-35 After complete two dose vaccination, the reference ranges (1–99 percentile) for all responders (fold–index \geq 4) were 43.9–592.0 BAU/mL. A preliminary cutoff of 50 BAU/mL was set based on percentiles of all responders and convenience of manufacturing standard controls. The final cutoff value will be determined by future clinical trials. The WHO IS has demonstrated to be enabled to comparison between different types of vaccines. Zitt et al. reported that the median titers of non-seroconversion and seroconversion were 635.5 and 1,565.0 BAU/mL after two doses of mRNA vaccination in hemodialysis patients at 67.6 ± 14.8 years, respectively;³⁶ whereas we reported that the median titers of non-seroconversion and seroconversion were 63.9 and 346.0 BAU/mL after giving two doses of inactivated SARS-CoV-2 vaccines at 67 ± 6 years, respectively, indicating that the mRNA vaccines is more potent than the inactivated SARS-CoV-2 vaccines.³⁷ The benefits of post-vaccination serologic testing outweigh the potential risks. Zitt et al. reported there were median titer of 1,440 BAU/mL in documented hepatitis B virus (HBV) vaccine responders (anti-HBs antibody ≥10 mIU/mL) and median titer of 308.5 BAU/mL in nonresponders after two doses of mRNA vaccination (P = 0.035), suggesting that post-vaccination testing might predict the general immune competence.36 All anti-SARS-CoV-2 spike IgGpositive patients recovered from the infection respond well to the vaccine, which indirectly

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

proves this phenomenon.²⁹⁻³⁰ If this theory turns out to be correct, then it is possible that SARS-CoV-2 vaccine responders have a strong ability to produce antibodies against variants through asymptomatic infections. This may support the Government-issued "immunity passports" to demonstrate an individual's immune ability according to the WHO IS (≥ 50 BAU/mL) after recovered from COVID-19 or SARS-CoV-2 vaccination. The most significant benefit of post-vaccination serologic testing is to save patient lives. Chukwu et al. reported clinical findings in a group of kidney transplant recipients vaccinated with 2 doses of vaccines (72% of BNT162b2, 28% of AZD1222). There were 22 breakthrough infections and 3 deaths after vaccination, including 77% (17/22) infections and 13.6% (3/22) deaths in the seronegative group and only 23% (5/22) infections and 0% (0/22) deaths in the seropositive group.³⁸ However, this study did not use the WHO IS to get a cutoff for the responder. Therefore, there may be some non-responders (fold-index <4) in the seropositive group according to our study. For SARS-CoV-2 vaccine non-responders, one benefit from post-vaccination serologic testing to the patient is to get a booster shot as soon as possible. 39-40 For persistent non-responders to SARS-CoV-2 vaccination, anti-SARS-CoV-2 antibody injections could save these lives in the seronegative group after the vaccination. 41-43 Another good example for post-vaccination serologic testing is the HBV vaccine. After the first hepatitis B vaccine was approved in the United States in 1981 and the recombinant hepatitis B vaccine developed by Maurice Hilleman was approved by the FDA in 1986, it took scientists more than 20 years to realize that the vaccine did not provide good protection for the elderly and certain immunocompromised populations and put them at risk of breakthrough infections after vaccination. 44-45 Szmuness et al. have first reported that 7.4% of immunized individuals fail to elicit detectable specific antibodies after two doses of hepatitis B vaccine, suggesting that there are non-responders in the population in 1982. 46 Roome et al. have found in 1993 that 11.9% of individuals with hepatitis B vaccine were no or inadequate levels of antibody, suggesting that post-vaccination testing should be done at intervals of 30 to 90 days after the last vaccine dose.⁴⁷ Many subsequent studies have shown that the elderly and immunocompromised populations are

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

associated with reduced vaccine responses to hepatitis B vaccination. 45-47 The CDC has recommended post-vaccination serologic testing using the WHO IS for immunocompromised individuals following HBV vaccination. ⁴⁵ For persistent non-responders (anti-HBs antibody <10 mIU/mL, the WHO IS 07/164) to HBV vaccination, anti-HBV Ig injections are recommended if exposed to HBV.45 Furthermore, the lower immune cell count may form the major risk factor for non-responders after administration of full SARS-CoV-2 vaccine in our study. Van Oekelen et al. have demonstrated that 32.3% (10/31) of multiple myeloma patients with severe lymphopenia (<500/mm³) remained negative for SARS-CoV-2 spike IgG after two doses of mRNA vaccines (OR 2.89, 95% CI 1.10–7.20, P = 0.018). Similarly, two studies reported that 63.7–77.3% of patients who had a history of anti-CD20 therapy for B cell depletion remained negative for SARS-CoV-2 IgG after receiving mRNA vaccines, suggesting that B cells are required for humoral immunity following COVID-19 vaccines. 49-50 Hence, further clinical trials must be performed to finalize effective booster shots for immunocompromised people after administering the complete dose in the general population. 51-55 According to this study, the anti-spike IgG seropositivities were 99.7% and 98.9% in the 18–59 vr and >60 vr groups, respectively. Additionally, certain naïve immune cells, such as CD4 cells, CD8 cells, and B cells exhibited significant waning in the elderly people, suggesting that the non-seroconversion rates were higher in individuals with lower immune cell counts. Incidentally, the anti-spike IgG seroprevalence or positivity was inconsistent with seroconversion rates observed in our study, thereby suggesting that anti-spike IgG positivity might not be a suitable predictor for the seroconversion rates. Our data showed that 7.5-11.7% of non-responders existed in the population, even some non-responders with anti-spike IgG positivity, supporting the CDC's concern that some non-responders are positive for anti-spike IgG after vaccination.⁵⁶ An FDA EUA quantitative assay with the WHO IS (20/136) may help to address this issue. 26-27 There are several potential strategies that can be employed to reduce the COVID-19 mortality rate below 0.13 % of that caused by influenza virus. These include the following measures: (1) Increase the vaccination rate of the population;² (2) Develop vaccines against emerging and

potential variants;⁵⁷⁻⁶² (3) Administer booster vaccines for non-responders;⁶³⁻⁶⁵ (4) Assessment of humoral immune response of children, the elderly, and immunocompromised persons within 1–3 months after 4th dose;^{45, 65-70} and (5) Incorporate additional protective measures for individuals with persistent (4th or 5th dose) negative humoral immune response after booster vaccination, such as injection of anti-SARS-CoV-2 immunoglobulins, antiviral drug treatment, usage of N95 masks in endemic areas, etc.^{41-43, 71-74}

CONCLUSIONS

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

297

302

Immune cells such as CD4 cells, CD8 cells, and B cells and anti-spike IgG levels were significantly reduced in the elderly. There were 7.5% non-responders among the 18–59 yr group and 11.7% in the \geq 60 yr group. A titer of anti-SARS-CoV-2 spike IgG is blew 50 BAU/mL to be considered as non-responders at intervals of 30 to 90 days after the last vaccine dose. Booster vaccination may be recommended for non-responders to reduce the disease severity and mortality.

ACKNOWLEDGMENTS

- **Limitations:** Study limitations include small sample size, data was only sourced from a single center, and lack of RBD/spike-specific cellular immune assessments.
- Funding: This work was supported by the project of "Antibody Immunity Evaluation after
- SARS-CoV-2 Vaccination in General Population" (Z211100002521024) from Beijing Science
- and Technology Commission.
- Author Contributions: Drs Zeng and Xu had full access to all of the data in the study and take
- responsibility for the integrity of the data and the accuracy of the data analysis. Drs Zeng and
- Yang served as co-first authors and contributed equally to the work. Concept and design: All
- authors. Acquisition, analysis, or interpretation of data: All authors. Drafting of the manuscript:
- and Xu. Statistical analysis: Zeng, Huang and Xu. Obtained funding: Zeng and Gao.
- Administrative, technical, or material support: Zeng, Yang, Lin, Xu. Supervision: Zeng and Xu.

Zeng and Xu. Critical revision of the manuscript for important intellectual content: Zeng, Huang

Institutional Review Board Statement: The study was approved by the institutional ethics committee (No. S2021-481-01). **Informed Consent Statement:** All study participants provided their informed written consent. **Competing interests**: None. **Data and materials availability**: All data are available in the manuscript or the supplementary materials.

REFERENCES

- 337 1. World Health Organization. WHO coronavirus (COVID-19) dashboard. https://covid19.who.int/
- 338 World Health Organization. COVID-19 advice for the public: Getting vaccinated.
- 339 https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines/advice
- 340 3. Centers for Disease Control and Prevention. Burden estimates for the 2016-2017 influenza season.
- 341 https://www.cdc.gov/flu/about/burden/2016-2017.html
- 342 4. Marks KJ, Whitaker M, Anglin O et al. Hospitalizations of children and adolescents with laboratory-confirmed
- 343 COVID-19 — COVID-NET, 14 States, July 2021–January 2022. Morbidity and Mortality Weekly Report (MMWR).
- 344 2022;71(7):271-278.
- 345 5. Tenforde MW, Self WH, Adams K et al. Association between mRNA vaccination and COVID-19 hospitalization
- 346 and disease severity. JAMA. 2021;326, 2043–2054. doi: 10.1001/jama.2021.19499.
- 347 6. Zeng Q, Li YZ, Dong SY et al. Dynamic SARS-CoV-2-specific immunity in critically ill patients with 348 hypertension. Front Immunol. 2020;11, 596684. doi: 10.3389/fimmu.2020.596684.
- 349 7. Lipsitch M, Krammer F, Regev-Yochay G et al. SARS-CoV-2 breakthrough infections in vaccinated individuals: 350 measurement, causes and impact. Nat. Rev. Immunol. 2022;22:57-65. doi: 10.1038/s41577-021-00662-4.
- 351 8. Sun J, Zheng Q, Madhira V et al. Association between immune dysfunction and COVID-19 breakthrough
- 352 infection after SARS-CoV-2 vaccination in the US. JAMA Intern. Med. 2022;182:153-162. doi:
- 353 10.1001/jamainternmed.2021.7024.
- 354 Johns **Hopkins** & Medicine. Understanding University vaccination progress.
- https://coronavirus.jhu.edu/vaccines/international 355
- 356 10. Xia SL, Zhang YT, Wang YX et al. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-
- 357 CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial. Lancet Infect Dis
- 2022; 22: 196-208. DOI:https://doi.org/10.1016/S1473-3099(21)00462-X. 358
- 359 11. Xia S, Duan K, Zhang Y et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and
- 360 immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA. 2020 Sep 8;324(10):951-960.
- 361 doi: 10.1001/jama.2020.15543.
- 362 12. Long QX, Liu BZ, Deng HJ et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med.
- 363 2020;26(6):845-848. doi: 10.1038/s41591-020-0897-1.
- 364 13. Weissman JY, Tsuchivose MM, Tong MJ et al. Lack of response to recombinant hepatitis B vaccine in 365 nonresponders to the plasma vaccine. JAMA. 1988;260(12):1734-1738.
- 14. Simon D, Tascilar K, Fagni F et al. Efficacy and safety of SARS-CoV-2 revaccination in non-responders with 366
- 367 immune-mediated inflammatory disease. Ann Rheum Dis. 2021; annrheumdis-2021-221554.
- 368 10.1136/annrheumdis-2021-221554.
- 369 15. Atmar RL, Lyke KE, Deming ME et al. Homologous and heterologous Covid-19 booster vaccinations. N Engl J
- 370 Med. 2022 Mar 17;386(11):1046-1057. doi: 10.1056/NEJMoa2116414.
- 371 16. Polack FP, Thomas SJ, Kitchin N et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J
- 372 Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577.
- 373 17. Wu K, Werner AP, Koch M et al. Serum neutralizing activity elicited by mRNA-1273 vaccine. N Engl J Med.
- 374 2021 Apr 15;384(15):1468-1470. doi: 10.1056/NEJMc2102179.
- 375 18. Benenson S, Oster Y, Cohen MJ et al. BNT162b2 mRNA Covid-19 vaccine effectiveness among health care
- 376 workers. N Engl J Med. 2021 May 6;384(18):1775-1777. doi: 10.1056/NEJMc2101951.
- 377 19. Dagan N, Barda N, Kepten E et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination
- 378 setting. N Engl J Med. 2021 Apr 15;384(15):1412-1423. doi: 10.1056/NEJMoa2101765.
- 379 20. Baden LR, El Sahly HM, Essink B et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J
- 380 Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389.
- 381 21. Wu K, Werner AP, Koch M et al. Serum neutralizing activity elicited by mRNA-1273 vaccine. N Engl J Med.
- 382 2021 Apr 15;384(15):1468-1470. doi: 10.1056/NEJMc2102179.
- 22. Boyarsky BJ, Werbel WA, Avery RK et al. Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in 383
- 384 solid organ transplant recipients. JAMA. 2021;325(21):2204-2206. doi: 10.1001/jama.2021.7489.
- 385 23. Goldshtein I, Nevo D, Steinberg DM et al. Association between BNT162b2 vaccination and incidence of SARS-
- 386 CoV-2 infection in pregnant women. JAMA. 2021;326(8):728-735. doi: 10.1001/jama.2021.11035.
- 387 24. Logunov DY, Dolzhikova IV, Shcheblyakov DV et al. Safety and efficacy of an rAd26 and rAd5 vector-based
- 388 heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.
- 389 Lancet. 2021;397(10275):671-681. doi: 10.1016/S0140-6736(21)00234-8.
- 390 25. Al Kaabi N, Zhang Y, Xia S et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19

- 391 infection in adults: A randomized clinical trial. JAMA. 2021;326(1):35-45. doi: 10.1001/jama.2021.8565.
- 392 26. Kristiansen PA, Page M, Bernasconi V et al. WHO International Standard for anti-SARS-CoV-2
- immunoglobulin. Lancet 2021;397:1347-1348. doi:10.1016/S0140-6736(21)00527-4.
- 394 27. Knezevic I, Mattiuzzo G, Page M et al. WHO International Standard for evaluation of the antibody response to
- 395 COVID-19 vaccines: call for urgent action by the scientific community. Lancet Microbe 2022;3: e235-40. doi:
- 396 10.1016/S2666-5247(21)00266-4.
- 28. Khoury DS, Cromer D, Reynaldi A et al. Neutralizing antibody levels are highly predictive of immune protection
- 398 from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205-1211. doi: 10.1038/s41591-021-01377-8.
- 29. Saadat S, Rikhtegaran Tehrani Z et al. Binding and neutralization antibody titers after a single vaccine dose in health care workers previously infected with SARS-CoV-2. JAMA. 2021;325(14):1467-1469. doi:
- 401 10.1001/jama.2021.3341.
- 402 30. Krammer F, Srivastava K, Alshammary H et al. Antibody responses in seropositive persons after a single dose of
- 403 SARS-CoV-2 mRNA vaccine. N Engl J Med. 2021;384(14):1372-1374. doi: 10.1056/NEJMc2101667.
- 404 31. Wajnberg A, Amanat F, Firpo A et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months.
- 405 Science. 2020;370:1227–1230. doi: 10.1126/science.abd7728.
- 406 32. Amanat F, Thapa M, Lei T et al. SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to
- 407 NTD, RBD, and S2. Cell. 2021;184(15):3936-3948.e10. doi: 10.1016/j.cell.2021.06.005.
- 408 33. Liu STH, Lin HM, Baine I et al. Convalescent plasma treatment of severe COVID-19: a propensity score-
- 409 matched control study. Nat. Med. 2020;26:1708–1713. doi: 10.1038/s41591-020-1088-9.
- 410 34. Amanat F, Stadlbauer D, Strohmeier S et al. A serological assay to detect SARS-CoV-2 seroconversion in
- 411 humans. Nat. Med. 2020;26: 1033–1036. doi: 10.1038/s41591-020-0913-5.
- 412 35. Dan JM, Mateus J, Kato Y et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after
- 413 infection. Science. 2021;371(6529):eabf4063. doi: 10.1126/science.abf4063.
- 414 36. Zitt E, Davidovic T, Schimpf J et al. The safety and immunogenicity of the mRNA-BNT162b2 SARS-CoV-2
- 415 vaccine in hemodialysis patients. Front Immunol. 2021;12:704773. doi: 10.3389/fimmu.2021.704773.
- 416 37. Sauré D, O'Ryan M, Torres JP et al. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2
- 417 COVID-19 vaccines in Chile: a sentinel surveillance study. Lancet Infect Dis. 2022;22(1):56-63. doi:
- 418 10.1016/S1473-3099(21)00479-5.
- 419 38. Chukwu CA, Mahmood K, Elmakki S et al. Evaluating the antibody response to SARS-COV-2 vaccination
- 420 amongst kidney transplant recipients at a single nephrology centre. PLoS One. 2022;17(3):e0265130. doi:
- 421 10.1371/journal.pone.0265130.
- 422 39. Accorsi EK, Britton A, Fleming-Dutra KE et al. Association between 3 Doses of mRNA COVID-19 vaccine and
- 423 symptomatic infectioncaused by the SARS-CoV-2 Omicron and Delta variants. JAMA. 2022;327(7):639-651. doi:
- 424 10.1001/jama.2022.0470.
- 425 40. Rottenberg Y, Grinshpun A, Ben-Dov IZ et al. Assessment of response to a third dose of the SARS-CoV-2
- 426 BNT162b2 mRNA vaccine in patients with solid tumors undergoing active treatment. JAMA Oncol. 2022;8(2):300-
- 427 301. doi: 10.1001/jamaoncol.2021.6764.
- 428 41. Weinreich DM, Sivapalasingam S, Norton T et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients
- 429 with Covid-19. N Engl J Med. 2021;384(3):238-251. doi: 10.1056/NEJMoa2035002.
- 43. 42. O'Brien MP, Forleo-Neto E, Musser BJ et al. Subcutaneous REGEN-COV antibody combination to prevent
- 431 Covid-19. N Engl J Med. 2021;385(13):1184-1195. doi: 10.1056/NEJMoa2109682.
- 43. Weinreich DM, Sivapalasingam S, Norton T et al. REGEN-COV antibody combination and outcomes in
- 433 outpatients with Covid-19. N Engl J Med. 2021;385(23):e81. doi: 10.1056/NEJMoa2108163.
- 434 44. Tulchinsky TH. Maurice Hilleman: Creator of vaccines that changed the world. Case Studies in Public Health.
- 435 2018;443–470. doi:10.1016/B978-0-12-804571-8.00003-2.
- 436 45. Mast EE, Weinbaum CM, Fiore AE et al. A comprehensive immunization strategy to eliminate transmission of
- 437 hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization
- 438 Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep. 2006;55(RR-16):1–33. quiz CE1-4.
- 439 46. Szmuness W, Stevens CE, Harley EJ et al. Hepatitis B vaccine in medical staff of hemodialysis units: efficacy
- 440 and subtype cross-protection. N Engl J Med. 1982;307(24):1481-6. doi: 10.1056/NEJM198212093072403.
- 441 47. Roome AJ, Walsh SJ, Cartter ML et al. Hepatitis B vaccine responsiveness in Connecticut public safety
- 442 personnel. JAMA. 1993;270(24):2931-4.
- 48. Van Oekelen O, Gleason CR, Agte S et al. Highly variable SARS-CoV-2 spike antibody responses to two doses
- of COVID-19 RNA vaccination in patients with multiple myeloma. Cancer Cell. 2021;39:1028-1030 (2021). doi:
- 445 10.1016/j.ccell.2021.06.014.
- 446 49. Ollila TA, Lu S, Masel R et al. Antibody response to COVID-19 vaccination in adults with hematologic

- 447 malignant disease. JAMA Oncol. 2021;7:1714–1716. doi: 10.1001/jamaoncol.2021.4381.
- 50. Greenberger LM, Saltzman LA, Senefeld JW et al. Antibody response to SARS-CoV-2 vaccines in patients with
- 449 hematologic malignancies. Cancer Cell. 2021;39:1031–1033. doi: 10.1016/j.ccell.2021.07.012.
- 450 51. Massarweh A, Eliakim-Raz N, Stemmer A et al. Evaluation of seropositivity following BNT162b2 messenger
- RNA vaccination for SARS-CoV-2 in patients undergoing treatment for cancer. JAMA Oncol. 2021;7(8):1133-1140.
- 452 doi: 10.1001/jamaoncol.2021.2155.
- 52. Obeid M, Suffiotti M, Pellaton C et al. Humoral responses against variants of concern by COVID-19 mRNA vaccines in immunocompromised patients. JAMA Oncol. 2022; e220446. doi: 10.1001/jamaoncol.2022.0446.
- 455 53. Maneikis K, Šablauskas K, Ringelevičiūtė U et al. Immunogenicity of the BNT162b2 COVID-19 mRNA
- vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study. Lancet Haematol. 2021;8(8):e583-e592. doi: 10.1016/S2352-3026(21)00169-1.
- 458 54. Kamar N, Abravanel F, Marion O et al. Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients. N Engl J Med. 2021;385(7):661-662. doi: 10.1056/NEJMc2108861.
- 55. Boyarsky BJ, Werbel WA, Avery RK et al. Antibody response to 2-Dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA. 2021;325(21):2204-2206. doi: 10.1001/jama.2021.7489.
- 462 56. Centers for Disease Control and Prevention. Using antibody tests for COVID-19 https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests.html
- 57. Lustig Y, Nemet I, Kliker L et al. Neutralizing response against variants after SARS-CoV-2 infection and one dose of BNT162b2. N Engl J Med. 2021 Jun 24;384(25):2453-2454. doi: 10.1056/NEJMc2104036.
- 58. Garcia-Beltran WF, St Denis KJ, Hoelzemer A et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell. 2022;185(3):457-466.e4. doi:
- 468 10.1016/j.cell.2021.12.033.
- 59. Collie S, Champion J, Moultrie H et al. Effectiveness of BNT162b2 vaccine against Omicron variant in South Africa. N Engl J Med. 2022;386(5):494-496. doi: 10.1056/NEJMc2119270.
- 471 60. Andrews N, Stowe J, Kirsebom F et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant.
- 472 N Engl J Med. 2022:NEJMoa2119451. doi: 10.1056/NEJMoa2119451.
- 473 61. Madhi SA, Kwatra G, Myers JE et al. Population immunity and Covid-19 severity with Omicron variant in
- 474 South Africa. N Engl J Med. 2022 Feb 23:NEJMoa2119658. doi: 10.1056/NEJMoa2119658. Online ahead of print
- 475 62. Lopez Bernal J, Andrews N, Gower C et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med. 2021;385(7):585-594. doi: 10.1056/NEJMoa2108891.
- 477 63. Hall VG, Ferreira VH, Ku T et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. N Engl J Med. 2021;385(13):1244-1246. doi: 10.1056/NEJMc2111462.
- 479 64. Benotmane I, Gautier G, Perrin P et al. Antibody response after a third dose of the mRNA-1273 SARS-CoV-2
- vaccine in kidney transplant recipients with minimal serologic response to 2 doses. JAMA. 2021;326(11):1063-5. doi: 10.1001/jama.2021.12339.
- 482 65. Kamar N, Abravanel F, Marion O et al. Assessment of 4 Doses of SARS-CoV-2 messenger RNA-based vaccine
- 483 in recipients of a solid organ transplant. JAMA Netw Open. 2021;4(11):e2136030. doi:
- 484 10.1001/jamanetworkopen.2021.36030.
- 485 66. Sfeir MM, Snayd M. Serologic testing for hepatitis B. JAMA. 2021 Dec 21;326(23):2423-2424. doi: 10.1001/jama.2021.19803.
- 487 67. Zheng H, Zhang GM, Chan PL et al. Compliance among infants exposed to hepatitis B virus in a post-488 vaccination serological testing program in four provinces in China. Infect Dis Poverty. 2019;8(1):57. doi:
- 489 10.1186/s40249-019-0568-y.
- 490 68. Trevisan A, Frasson C, De Nuzzo D et al. Significance of anti-HB levels below 10 IU/L after vaccination against
- hepatitis B in infancy or adolescence: an update in relation to sex. Hum Vaccin Immunother. 2020;16(2):460-464.
- 492 doi: 10.1080/21645515.2019.1656483.
- 493 69. Le MH, Yeo YH, So S et al. Prevalence of hepatitis B vaccination coverage and serologic evidence of immunity
- 494 among US-born children and adolescents from 1999 to 2016. JAMA Netw Open. 2020;3(11):e2022388. doi: 10.1001/jamanetworkopen.2020.22388.
- 70. Wood RC, MacDonald KL, White KE et al. Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers. JAMA. 1993;270(24):2935-9.
- 498 71. Wen W, Chen C, Tang J et al. Efficacy and safety of three new oral antiviral treatment (molnupiravir,
- 499 fluvoxamine and Paxlovid) for COVID-19:a meta-analysis. Ann Med. 2022 Dec;54(1):516-523. doi:
- 500 10.1080/07853890.2022.2034936.
- 501 72. Mahase E. Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of serious illness, company reports.
- 502 BMJ. 2021;375:n2713. doi: 10.1136/bmj.n2713.

503 73. Gandhi RT, Malani PN, Del Rio C. COVID-19 therapeutics for nonhospitalized patients. JAMA. 504 2022;327(7):617-618. doi: 10.1001/jama.2022.0335.

74. Baker MA, Rhee C, Tucker R et al. Rapid control of hospital-based SARS-CoV-2 omicron clusters through daily testing and universal use of N95 respirators. Clin Infect Dis. 2022 Feb 7:ciac113. doi: 10.1093/cid/ciac113.

Figures




Fig. 1. Immune characteristics of 627 individuals. (A) Naïve cellular immune parameters of the 627 cases who received physical examinations. These naïve immune cells wane significantly, while the natural killer (NK) cell counts increase significantly in the elderly people. ALC = absolute lymphocyte count. (B) The anti-spike IgG levels after complete vaccination of the 627 cases. The quantitative level of the anti-spike IgG was significantly lower in the ≥60 yr group (median 307.2, IQRs 118.2–417.3 BAU/mL) than that in the 18–59 yr group (median 416.8, IQRs 355.7–479.2 BAU/mL, P < 0.001. Mean and standard error of the mean (SEM) were shown. (C) The vaccine-induced responses using the 4-fold increase after complete vaccination of the 627 cases. There were 7.5% non-responders (fold-index < 4) among the 18–59 yr group and 11.7% in the ≥60 yr group. The reference ranges (1–99 percentile) for responders (fold-index ≥ 4) were 43.9–592.0 BAU/mL in combination of the 18–59 yr group and the ≥60 yr group. A cutoff line at fold-index 4 was showed. (D) In the responder group (fold-index ≥ 4), intervals for 1–99 percentile were 131.8–592.3 BAU/mL in the 18–59 yr group, and 29.7–500.9 BAU/mL in the ≥60 yr group, respectively. Mean and standard error of the mean (SEM) were shown.

Tables

Table 1. Immune characteristics of individuals before and after vaccination

Characteristics	18-59 yr group	≥60 yr group	P value
Total number of cases	361	266	
Sex (%)			
Male	183 (50.7)	136 (51.1)	
Female	178 (49.3)	130 (48.9)	
Mean age (SD) in yr	45 (9)	67 (6)	
Naïve immune cells, median (IQRs)			
Lymphocytes (/mm³)	1,476	1,281	< 0.001
CD4 cells (/mm³)	(1,168–1,875) 851	(1,023–1,520) 747 (562,055)	< 0.001
CD8 cells (/mm³)	(677–1,151) 490	(562–955) 418	< 0.001
B cells (/mm³)	(357–632) 256 (179–367)	(288–544) 204 (138–303)	< 0.001
Natural killer cells (/mm ³)	193 (141–287)	234 (162–355)	< 0.001
Anti-spike IgG			
Seropositivity % (no.)	99.7 (360/361)	98.9 (263/266)	
Median (IQRs) (BAU/mL)	416.8 (355.7–479.2)	307.2 (118.2–417.3)	< 0.001

601

Characteristics Groups	18-59 yr group		≥60 yr group			
	Fold-index <4	Fold–index ≥4	P value	Fold-index <4	Fold–index ≥4	P value
Total number of cases	361			266		
Anti-spike IgG BAU/mL (2.5–97.5 percentile)	88.6–576.2			27.7–491.0		
Fold-index % (no.)*	7.5 (27/361)	92.5 (334/361)		11.7 (31/266)	88.3 (235/266)	
Anti-spike IgG BAU/mL						
Median (IQRs)	115.8 (88.6–167.8)	420.8 (369.9–480.6)	< 0.0001	63.9 (35.1–106.9)	346.0 (160.4–424.7)	< 0.0001
2.5–97.5 percentile	18.3–266.3	200.7–576.5		5.4–317.8	46.6–491.1	
Naïve immune cells (/mm³)						
Lymphocytes, mean (95% CI)	1,130 (1,007–1,252)	1,578 (1,524–1,633)	< 0.0001	1,015 (888–1,143)	1,344 (1,291–1,397)	< 0.0001
CD4 cells, mean (95% CI)	631 (555–708)	942 (905–979)	< 0.0001	563 (494–631)	818 (777–858)	< 0.0001
CD8 cells, mean (95% CI)	414 (349–479)	532 (508–557)	0.0081	394 (310–478)	444 (420–468)	0.1744
B cells, mean (95% CI)	119 (72–166)	306 (289–323)	< 0.0001	74 (60–88)	248 (231–266)	< 0.0001
NK cells, mean (95% CI)	192 (151–233)	235 (220–251)	0.1241	281 (225–337)	286 (261–311)	0.8902

^{*}Post-vaccination testing was done at intervals of 14 to 90 days after the second vaccine dose. The reference ranges were defined as the 2.5–97.5 percentile in the study.